Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Molecular Imaging|April 1, 2016
Immunotargeting of Integrin α6β4 for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer ModelWinn Aung, Atsushi B Tsuji, Hitomi Sudo, et al.
Cancer Science|December 22, 2021
FZD10-targeted α-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma modelHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Plos One|March 22, 2013
Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancerChisato Yoshida, Atsushi B Tsuji, Hitomi Sudo, et al.
Cancer Science|October 2, 2023
Head-to-head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti-FZD10 antibody OTSA101Hitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
International Journal of Oncology|October 19, 2018
Direct comparison of 2‑amino[3‑11C]isobutyric acid and 2‑amino[11C]methyl‑isobutyric acid uptake in eight lung cancer xenograft modelsHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
International Journal of Molecular Sciences|April 30, 2021
In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger ElectronsHonoka Obata, Atsushi B Tsuji, Hitomi Sudo, et al.
Nuclear Medicine Communications|September 19, 2022
Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing miceHonoka Obata, Atsushi B Tsuji, Hitomi Sudo, et al.
Oncology Reports|March 28, 2015
Preclinical assessment of early tumor response after irradiation by positron emission tomography with 2-amino-[3-¹¹C]isobutyric acidAtsushi B Tsuji, Aya Sugyo, Hitomi Sudo, et al.
Biochemical and Biophysical Research Communications|June 28, 2005
A fast, simple method for screening radiation susceptibility genes by RNA interferenceAtsushi B Tsuji, Hitomi Sudo, Aya Sugyo, et al.
Cells|October 23, 2021
Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant MesotheliomaHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Pageof 6